Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Clinicopathological Features and Prognosis of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma with t(14;18) and 8q24 Translocation in the Rituximab Era

Nozomi Niitsu, MD, PhD, Naoki Takahashi, Mika Kohri, Norio Asou, MD PhD, Jun-ichi Tamaru, Jun Sakai, Shigeo Nakamura, Ikuo Miura, Masataka Okamoto

Blood (2014) 124 (21): 1633.

https://doi.org/10.1182/blood.V124.21.1633.1633

Published: 2014

Journal Articles

Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis.

Shigeru Kusumoto, MD, PhD, Yasuhito Tanaka, MD, PhD, Ritsuro Suzuki, M.D., Takashi Watanabe, MD, PhD, Masanobu Nakata, MD, Hirotaka Takasaki, MD, Noriyasu Fukushima, MD, PhD, Takuya Fukushima, MD, PhD, Yukiyoshi Moriuchi, MD, Kuniaki Itoh, MD, PhD, Kisato Nosaka, MD, PhD, Ilseung Choi, MD, Masashi Sawa, MD, PhD, Rumiko Okamoto, MD, Hideki Tsujimura, MD, PhD, Toshiki Uchida, MD, PhD, Sachiko Suzuki, MD, PhD, Masataka Okamoto, MD, PhD, Tsutomu Takahashi, MD, PhD, Isamu Sugiura, MD, PhD, Yasushi Onishi, MD, PhD, Mika Kohri, MD, PhD, Shinichiro Yoshida, MD, PhD, Rika Sakai, MD, Minoru Kojima, MD, PhD, Hiroyuki Takahashi, MD, PhD, Akihiro Tomita, MD, PhD, Dai Maruyama, MD, PhD, Yoshiko Atsuta, MD, PhD, Eiji Tanaka, MD, PhD, Takayo Suzuki, MD, PhD, Tomohiro Kinoshita, M.D., Ph.D., Michinori Ogura, MD, PhD, Masashi Mizokami, MD, PhD, Ryuzo Ueda, MD, PhD

Blood (2012) 120 (21): 2641.

https://doi.org/10.1182/blood.V120.21.2641.2641

Published: 2012

Journal Articles

Prospective Analysis of Hepatitis B Virus Reactivation In Patients with Diffuse Large B Cell Lymphoma After Rituximab Combination Chemotherapy

Nozomi Niitsu, MD, Yuki Hagiwara, Ken Tanae, Mika Kohri, Miyuki Hayama, MD, PhD, Naoki Takahashi

Blood (2010) 116 (21): 3950.

https://doi.org/10.1182/blood.V116.21.3950.3950

Published: 2010

Journal Articles

Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.

Miyuki Hayama, Masataka Okamoto, MD, PhD, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Tadashi Yoshino, Koichi Ohshima, Nozomi Niitsu, MD

Blood (2010) 116 (21): 1800.

https://doi.org/10.1182/blood.V116.21.1800.1800

Published: 2010

Journal Articles

Multicenter Phase II Study of the CyclOBEAP Regimen for Patients with Peripheral T-Cell Lymphoma with Analysis of Biomakers.

Nozomi Niitsu, MD, PhD, Miyuki Hayama, MD, PhD, Yuki Hagiwara, Ken Tanae, Mika Kohri, Naoki Takahashi, Shigeo Nakamura, MD, Jun-ichi Tamaru, Masataka Okamoto, MD, PhD

Blood (2010) 116 (21): 2795.

https://doi.org/10.1182/blood.V116.21.2795.2795

Published: 2010

Journal Articles

Multicenter Phase II Study of the CyclOBEAP Plus Rituximab in Diffuse Large B-Cell Lymphoma with Analysis of Biomakers.

Nozomi Niitsu, Mika Kohri, Yuki Hagiwara, Ken Tanae, Handa Kohsuke, Naoki Takahashi, Masami Bessho, Masataka Okamoto

Blood (2009) 114 (22): 2725.

https://doi.org/10.1182/blood.V114.22.2725.2725

Published: 2009

NARROW

Clinicopathological Features and Prognosis of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma with t(14;18) and 8q24 Translocation in the Rituximab Era

Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis.

Prospective Analysis of Hepatitis B Virus Reactivation In Patients with Diffuse Large B Cell Lymphoma After Rituximab Combination Chemotherapy

Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.

Multicenter Phase II Study of the CyclOBEAP Regimen for Patients with Peripheral T-Cell Lymphoma with Analysis of Biomakers.

Multicenter Phase II Study of the CyclOBEAP Plus Rituximab in Diffuse Large B-Cell Lymphoma with Analysis of Biomakers.

Email alerts

ASH Publications

American Society of Hematology

Clinicopathological Features and Prognosis of B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma with t(14;18) and 8q24 Translocation in the Rituximab Era

Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis.

Prospective Analysis of Hepatitis B Virus Reactivation In Patients with Diffuse Large B Cell Lymphoma After Rituximab Combination Chemotherapy

Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.

Multicenter Phase II Study of the CyclOBEAP Regimen for Patients with Peripheral T-Cell Lymphoma with Analysis of Biomakers.

Multicenter Phase II Study of the CyclOBEAP Plus Rituximab in Diffuse Large B-Cell Lymphoma with Analysis of Biomakers.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only